Allovir, Inc. (ALVR, Financial) experienced a notable stock price increase of 5.06% as per recent data. The share price reached $0.830 with a trading volume of 89,091 shares, reflecting a turnover rate of 0.08% and a price fluctuation amplitude of 8.10%.
The latest financial reports from Allovir indicate no revenue, a net loss of $6.08 million, an earnings per share of -$0.05, and a gross profit of $0. The price-to-earnings ratio stands at -0.66. Among the institutions evaluating the stock, 33% have issued a hold recommendation, while 67% suggest selling. No institutions have recommended buying the stock.
Within the biotechnology sector, where Allovir operates, the overall increase has been 0.61%. Some related companies, including Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 (To Pur Com), Iterum Therapeutics Plc, and Immunitybio, Inc., showed significant gains. Meanwhile, 180 Life Sciences Corp., Elevai Labs, Inc., and Iterum Therapeutics Plc have seen high trading activity with turnover rates of 854.33%, 785.10%, and 385.96% respectively. Stocks with notable price fluctuation include Iterum Therapeutics Plc, Elevai Labs, Inc., and Qualigen Therapeutics, Inc., with amplitudes of 102.56%, 93.82%, and 91.58% respectively.
Allovir, Inc. is a late-stage clinical company specializing in cell therapy. It focuses on developing groundbreaking allogeneic T cell therapies to combat viral diseases. The company's proprietary VST therapy platform seeks to create ready-to-use VSTs to address the urgent medical needs of patients with limited treatment options for viral diseases. The platform is dedicated to the research, development, and commercialization of treatments for 11 destructive viruses, with posoleucel targeting six of these as a primary candidate. The company operates in a niche market, primarily focusing on the prevention and treatment of severe virus-related diseases through its VST therapy approach.
